Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF